Invest in Meta-IQ
Meta-IQ is an innovative biopharmaceutical company that develops drugs for the treatment of brain diseases.
At the moment Meta-IQ is looking for investment to test its medicine in two phase 2 clinical trials in patients suffering from Multiple Sclerosis and Depression.
For Multiple Sclerosis no treatment is available on the market that is able to help patients suffering from this disease. On this background together with the results in animals studies we have seen with the medicine MIQ-003, Multiple Sclerosis has been chosen as the first indication.
With MIQ-002, Meta-IQ has seen remarkeble results in the treatment of Depression, therefore, Meta-IQ has chosen Depression as the second indication for clinical trials.
In addition the Drug has shown excelllent results in restoring short and long term memory loss, which backup Meta-IQs hypothesis on the ability of its medicine to restore neuronal functioning.
You can find more information about Meta-IQ and this investment opportunity in the following presentation:
To perform these two phase 2 clinical trials Meta-IQ is looking for an investment of 9,5 million €.
|
Management
